La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Dextech Medical Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Anders Holmberg

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	20.6yrs
Proprietà del CEO	8.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	10.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

Feb 17

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Dec 12

AMMINISTRATORE DELEGATO

Anders Holmberg (73 yo)

20.6yrs

Mandato

SEK 596,112

Compensazione

Mr. Anders Ragnarsson Holmberg, M.D. is the Founder of Dextech Medical AB (publ) and serves as its Chief Executive Officer and Managing Director and served as its President. Mr. Holmberg has been a Directo...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Anders Holmberg	Founder	20yrs	SEK 596.11k	8.51% SEK 7.2m
Peter Benson	Director	1.6yrs	Nessun dato	Nessun dato
Meir Wilchek	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Rolf Eriksson	Director	10.4yrs	Nessun dato	Nessun dato
Svante Wadman	Director	no data	Nessun dato	21.47% SEK 18.3m
Per Asplund	Director	11.4yrs	Nessun dato	Nessun dato
Lennart Meurling	Member of Scientific Advisory Board	no data	Nessun dato	1.56% SEK 1.3m
Marcela Marquez	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ulf Lerner	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Andreas Segerros	Chairman of the Board	2.3yrs	Nessun dato	Nessun dato

10.4yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di DEX è composto da personale esperto e esperto (durata media dell'incarico 10.4 anni).

Dextech Medical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

No independent directors

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

No independent directors

Recent updates

Dextech Medical AB Announces Continued Positive Results from Myeloma Study

Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023)

DexTech Medical Announces New Positive Results from the Myeloma Study

New major risk - Market cap size

Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Share price stability

Dextech Medical AB Announces Positive Results from the Myeloma Study

DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023)

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.31 loss in FY 2022)

New minor risk - Share price stability

Third quarter 2023 earnings released: kr0.079 loss per share (vs kr0.061 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.076 loss in 2Q 2022)

Dextech Medical AB to Report Fiscal Year 2024 Results on Aug 30, 2024

No independent directors

First quarter 2023 earnings released: kr0.044 loss per share (vs kr0.063 loss in 1Q 2022)

Dextech Medical AB Announces Upcoming Multiple Myeloma Study

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.41 loss in FY 2021)

Dextech Medical AB to Report Q1, 2023 Results on Oct 27, 2022

Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

Third quarter 2022 earnings released: kr0.061 loss per share (vs kr0.10 loss in 3Q 2021)

No independent directors

DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

DexTech Medical AB Plans New Clinical Study on Multiple Myeloma

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

DexTech Medical AB Confirms Very Positive Results from Myeloma Studies

Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 3Q 2020)

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

New 90-day high: kr59.40

Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 2Q 2020)

DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma

New 90-day low: kr45.20

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

First quarter earnings released

Full year earnings released - kr0.52 loss per share

Full year earnings released - kr0.52 loss per share

New 90-day low - kr38.00

New 90-day low - kr42.00

New 90-day low - kr45.00

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media